Waiakea, the Impactful Bottled Water Company

Waiakea is the first Hawaiian Bottled volcanic water brand, it is now ranked 414 on the Inc. 5000 list of the loftiest growing companies in America. Waiakea’s bottled water company has a very high growth rate, which it has experience for the last three years it has been listed at a more prestigious group of Inc. 500. The Inc. 500 consist of the great companies such as GoPro, Microsoft, Zappos, Patagonia, Under Armour, and Timberland. This is an annual ranking that is done according to their revenue growth rate in three years.

Waiakea has experienced remarkable growth of 1,059.3% between 2014 to 2016. The most prestigious water bottled brand is celebrating it being part of the elite companies be acknowledged at the 2017 Inc. 5000 that will be held in California on Oct 10.

According to Ryan Emmons, the CEO and the founder of the Waiakea, the company is happy that they have managed to move from the top 500 of Inc. 5000 list. He went on to state that the firm has been working toward this achievement since the founding of the enterprise. He said that he was pleased with their performance and he anticipates a better and more productive future for the business.

Founded in 2012, Waiakea is the first brand in Hawaii for the Volcanic Water. The prestigious brand is produced on the specific objectives of health, charitable, and sustainable characteristics and programs. Waiakea Hawaiian Volcanic has a goal to offer naturally healthy water through an agreeable lifestyle brand that seeks to motivate and develop real positive changes in different ways. One of the best creations of the brand is the implementation of a triple bottom line model that is geared toward not only making profits but also care about the human race and the entire world. The brand contributes and access of the ready availability of clean water, the environmental conservation and educate a large number of people in America and various parts of the planet.

Apart from being a leading water bottle company, Waiakea has been involved in some leadership initiatives around the world. These initiatives are consultants work that aim to help companies such as Ecometrica and CarbonNeutral. The objective is to reduce their environmental impacts from their products and business activities to zero. Waiakea brand has endeavored to transform the world by making a positive impact around the world.

Amicus Therapeutics Is Saving Lives

Amicus Therapeutics is a pharmaceutical company that develops medications, and drug treatment plans for people with rare genetic disorders. The company was first established in Cranbury, New Jersey in the year 2002. Amicus Therapeutics has grown tremendously since then and became a publicly traded company in 2007. Amicus Therapeutics specializes in developing drug treatments for people with lysosomal storage disorders. Lysosomal storage disorders are a category of genetic disorders that affect the body’s ability to metabolize fats and proteins.

People who were born with a lysosomal storage disorder need constant medical treatment in order to live a normal life. If left untreated, a person with a lysosomal storage disorder will suffer from nerve damage, organ failure, and eventually, would die.

Amicus Therapeutics will change the lives of thousands of people through the development of new drugs, like migalastat.

Migalastat is currently the only medication made by Amicus Therapeutics that is out on the market. Migalastat is only available in Europe, where they have branded it as Galafold. Galafold is used in the treatment of Fabry Disease. There is no cure for Fabry Disease.

Although Amicus Therapeutics is not the first company to develop this kind of medicine, it enters a section of the pharmaceutical industry where there is a lot of room for growth (YahooFinance). People with these kinds of rare diseases will need as many options as they can get.

People with Fabry Disease suffer from:

  • Gastrointestinal problems
  • Burning sensations in the hands and feet
  • Hearing loss
  • Cloudy vision
  • Joint pain
  • Tinnitus
  •  Abdominal pain

https://www.glassdoor.com/Reviews/Amicus-Therapeutics-Reviews-E26068.htm

 

On July 11, 2017, Amicus Therapeutics got permission from the U.S. FDA to submit a new drug application for migalastat. There is already a lot of data from clinical research trials which support the effectiveness of migalastat. Migalastat works by replacing the patient’s defective enzymes with stable ones, and when this happens cells can begin removing waste normally.

Check out Amicus Therapeutics on